Last reviewed · How we verify
SCIO-469
At a glance
| Generic name | SCIO-469 |
|---|---|
| Sponsor | Scios, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. (PHASE2)
- A Study of Oral SCIO-469 Pharmacokinetics (Study of a Drug in the Body to Watch How the Drug is Absorbed, Distributed, Metabolized and Eliminated Over a Period of Time) in the Body of Female Patients With Active Rheumatoid Arthritis (PHASE1)
- Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (PHASE2)
- Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma (PHASE2)
- SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate (PHASE2)
- Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCIO-469 CI brief — competitive landscape report
- SCIO-469 updates RSS · CI watch RSS
- Scios, Inc. portfolio CI